Why the Coming Year Will Make or Break Biogen's Stock
For Biogen (NASDAQ: BIIB) and its investors, the next 12 months may result in great opportunity or dashed hopes. A lot is riding on a patent appeal concerning Biogen's blockbuster multiple sclerosis (MS) drug, Tecfidera, and a U.S. Food and Drug Administration decision on the company's potential Alzheimer's disease treatment called aducanumab.
Image source: Getty Images.
Considering the market crash in March, shares of the biotech giant haven't performed too badly. The stock is only down a little more than 8% this year. What happens with Tecfidera and aducanumab will offer further direction.
Source Fool.com
